Back to Journals » OncoTargets and Therapy » Volume 11

Profile of abemaciclib and its potential in the treatment of breast cancer

Authors Martin JM, Goldstein LJ

Received 11 April 2018

Accepted for publication 23 June 2018

Published 29 August 2018 Volume 2018:11 Pages 5253—5259


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly

James M Martin,1 Lori J Goldstein2

1Department of Medicine, Section of Hematology/Oncology, Temple University Hospital, Philadelphia, PA, USA; 2Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

Abstract: Hormone-receptor-positive breast cancer is the most common subtype of breast cancer among patients with both early-stage and metastatic disease. Recent advances in the understanding of its pathophysiology have led to the discovery and utilization of targeted inhibitors to cyclin-dependent kinases 4 and 6 (CDK4/6). There are currently three available CDK4/6 inhibitors available for use in USA: palbociclib, ribociclib, and abemaciclib. Their oral administration and tolerable toxicities make this class of agents appealing to both patients and health care providers. Abemaciclib, the most recently approved CDK4/6 inhibitor, has unique pharmacologic properties and potential toxicities. This review highlights the current understanding of abemaciclib and discusses its current and future roles in the treatment of breast cancer.

Keywords: abemaciclib, cyclin D1, breast cancer, CDK4/6

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]